SB 477-FN (2026): relative to increasing transparency in the 340B Drug Pricing Program.
Cite this page
Granite Record indexes the General Court’s record; it is not that record. Where a citation allows only one source, cite the General Court — every page here links to what it is drawn from. The date below is the day the page was read.
- MLA
- “SB 477-FN (2026): relative to increasing transparency in the 340B Drug Pricing Program.” Granite Record, https://graniterecord.org/bill/2026/sb477. Accessed 19 Oct. 2026.
- APA
- Granite Record. (n.d.). SB 477-FN (2026): relative to increasing transparency in the 340B Drug Pricing Program. Retrieved 19 Oct. 2026, from https://graniterecord.org/bill/2026/sb477
- Chicago
- Granite Record. “SB 477-FN (2026): relative to increasing transparency in the 340B Drug Pricing Program.” Accessed 19 Oct. 2026. https://graniterecord.org/bill/2026/sb477.
- BibTeX
@misc{bill-2026-sb477, title = {SB 477-FN (2026): relative to increasing transparency in the 340B Drug Pricing Program.}, howpublished = {Granite Record}, url = {https://graniterecord.org/bill/2026/sb477}, note = {Accessed 19 Oct. 2026} }
SB 477-FN (2026)
relative to increasing transparency in the 340B Drug Pricing Program.
- Status: Referred for interim study
- Term: 2025-2026
- Senate committee: Health and Human Services
- Subject: Public and Mental Health
The Story
It was introduced on January 7, 2026 and referred to the Senate Health and Human Services committee. The committee held a public hearing on January 21, 2026. The committee voted unanimously, 5–0, to recommend that the Senate study it after the session ends, and the report was placed on the consent calendar. The bill was taken off the consent calendar on February 19, 2026. On February 19, 2026 the Senate adopted “Special Order to the Next Session, Without Objection”. The committee voted unanimously, 5–0, to recommend that the Senate study it after the session ends. On March 5, 2026 the Senate adopted “Refer to Interim Study” on a voice vote.
Sponsors
- Sen. Tim McGough (R - SD11) (prime sponsor)
- Rep. Keith Ammon (R - Hills 42)
- Sen. Regina Birdsell (R - SD19)
- Rep. Brian Cole (R - Hills 26)
- Sen. Bill Gannon (R - SD23)
- Sen. Daniel Innis (R - SD7)
- Rep. Katelyn Kuttab (R - Rock 17)
- Rep. Wayne MacDonald (R - Rock 16)
- Rep. Julie Miles (R - Hills 12)
- Sen. Howard Pearl (R - SD17)
Hearings and Sessions
- January 21, 2026, 1:30 PM: hearing, Senate Health and Human Services, SH 100
- February 19, 2026: floor debate, Senate
- March 5, 2026: floor debate, Senate
Votes
- March 5, 2026, Senate: Refer to Interim Study — voice vote, passed
The Docket
- January 7, 2026: Introduced 01/07/2026 and Referred to Health and Human Services
- January 21, 2026: Hearing: 01/21/2026, Room 100, SH, 01:30 pm
- February 19, 2026: Committee Report: Referred to Interim Study, 02/19/2026; Vote 5-0; CC
- February 19, 2026: SB 477 was Removed from the Consent Calendar; 02/19/2026
- February 19, 2026: Special Order to the Next Session, Without Objection, MA; 02/19/2026
- March 5, 2026: Committee Report: Referred to Interim Study, 03/05/2026, Vote 5-0
- March 5, 2026: Refer to Interim Study, MA, VV; 03/05/2026